Connect with us

Cannabis News

Trump’s Marijuana Order Means Congress Must Delay The Federal Hemp Ban’s Timeline (Op-Ed)

Published

on

“Congress, you have orders from the president. Extend the implementation period of the hemp ban.”

By Adam Terry, Cantrip

As it was widely reported, last week the entire cannabis universe watched as President Donald Trump signed an executive order to change marijuana from schedule I to III. What wasn’t as widely reported was what Trump also did: He addressed lawmakers again on the law As Congress passed the new definition of hemp last month.

The exact text of the executive order reads:

“The Assistant to the President and Deputy Chief of Staff for Legislative, Policy, and Public Affairs will work with Congress to update the final statutory definition of hemp-derived cannabinoid products to ensure that Americans have access to appropriate full-spectrum CBD products, in line with Congress’ intent to reduce the sale of products that pose serious health risks…”

This provision is careful and detailed. He directs a deputy chief of staff to work with Congress to update the new definition of hemp, directly acknowledging what the hemp industry has been saying for weeks: full-spectrum CBD products are not eligible under this new language.

He specifically acknowledges that if CBD products are to be subsidized or covered by Medicare, as is part of Trump’s plan, those products will be hemp-derived.

Full-spectrum CBD is a staple for many Americans. It is a lifesaver for veterans and senior citizens who rely on these products for various therapeutic purposes. It is a crucial element for some people with epilepsy, including pediatric patients. I’ve had moms and dads message me that Epidiolex, a federally approved CBD prescription drug, wasn’t working for their kids, and instead they were relying on other CBD products to find relief for their kids.

This is not just politics for them, but a stark reality.

You can’t have full-spectrum CBD with only 0.4 mg of THC per container, as required by the newly enacted change to the federal definition of hemp, and the president acknowledged that in his executive order, I’m sure with counsel to groups like the Commonwealth Project who were at the signing. Therefore, it is very likely that the definition of hemp will be reopened and legalized.

So here’s the bottom line: this conversation will take time, and probably longer than hemp has left before the ban comes into force late next year. While I have been working with the New Jersey legislature for nearly three years to craft a bill to regulate hemp cannabinoids in a way that does not diminish the CBD market, it has yet to make full impact in the state due to this complexity.

This means that the best first step for Congress to take is to extend the deadline for implementing a revised definition of hemp to ensure access to full-spectrum CBD for the tens of millions of Americans who will lose access next November if this language is enacted.

With 2026 being a close election year, most legislation will slow down after April, so it is unlikely that a final bill updating this language and regulating hemp cannabinoids will reach the finish line until the next Congress, which begins in January 2027. And the extension must pass soon, because farmers can’t plant in the spring if their harvest is in time.

I look forward to the next interview. Hemp needs to be regulated in this country, that much is clear. The White House has just sent a signal that prohibitionist redefinition cannot stand if the people who rely most on cannabis are to do well, especially in red states that voted for this president and those who have no access to cannabis outside of hemp products.

Congress, you have orders from the president. Extend the implementation period of the hemp ban, and let’s do the real hard work to craft legislation that includes safe access to cannabis for Americans in this great nation.

Adam Terry is the co-founder and CEO of THC-infused beverage company Cantrip.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

From photobiology to dynamic lighting strategies in greenhouse production

Published

on

By

Greenhouse growers are working in conditions where crop yield and energy use must be managed simultaneously. According to Timo Spruijt, Chief Customer Officer at RED Horticulture, this requires a shift from fixed lighting schedules to approaches based on plant light responses.

“Lighting is moving from static control to measured and predictable strategies,” says Timo. “That starts with understanding how plants react to light and translating that into everyday decisions.”

© RED Horticulture

This approach is based on photobiology, which links plant development to light conditions. Two parameters are central: intensity and spectrum. Light intensity affects photosynthesis, biomass accumulation and yield, while spectrum affects morphology, flowering, rooting and nutritional composition. Paul Vailhen, photobiologist at RED, points out that these factors must be managed together. “Focusing on one parameter without the other limits how plants use light. The interaction between intensity and spectrum determines photon efficiency.”

He explained that growers can use this knowledge to target harvests more precisely. “When photobiology is applied in practice, lighting becomes a management tool rather than a fixed input.”

Three areas
To support this, RED Horticulture organizes its offer around three areas: luminaires, control platform and agronomic orientation. These components are intended to respond to changes during the day and during the cultivation phases. “The needs of the plants are not constant,” says Timo. “Lighting strategies must follow these variations.”

The MyRED platform is used to translate greenhouse data into lighting decisions. Growers can monitor performance and adjust lighting strategies through a dashboard. “The platform allows producers to define and modify their light recipes and evaluate the results,” explains Timo. “It links crop data with energy use.”

He added that implementation goes beyond software. “Support continues after installation. We work with growers to set goals, apply strategies and adjust over time.”

Energy use
Energy use is a major factor in greenhouse operations. Timo connects lighting strategies directly with consumption. “Understanding how intensity and spectrum affect power use helps growers manage their energy input,” he says. “This could lead to changes in the way lighting is applied during the day.”

Automation is also part of today’s greenhouse practices. The system can adjust the lighting throughout the day according to predefined strategies. “Automation reduces manual adjustments and keeps light levels consistent,” says Timo. “It also allows control over the entire light output.”

He noted that automated control can contribute to additional energy savings beyond the performance of the luminaires. “When strategies are applied dynamically, further reductions in energy use are possible.”

Research
This is another part of the research approach. Through the Photobiology and Agronomy Research Center (PARC), RED Horticulture conducts trials under controlled conditions. Timo explains how this relates to commercial production. “Trials allow strategies to be tested before implementation. Producers can then apply these results with a clearer view of expected outcomes.”

The goal is to make photobiology applicable to different crops and growing environments. “The same principles can be adapted to different varieties and production systems,” says Timo. It concludes by returning to the role of knowledge in greenhouse management. “Understanding photobiology is the starting point. From there, growers can build lighting strategies that match crop requirements and energy constraints.”

For more information:
RED Horticulture
World Horti Center
Europe 1
2672 ZX Naaldwijk
+31 174 705 617
horticulture.red/

Continue Reading

Cannabis News

Hawaii Lawmakers Approve Bill To Create Psychedelics Task Force Charged With Studying Psilocybin And MDMA

Published

on

By

Another Hawaii House committee has passed the Senate-passed bill creating a psychedelic task force responsible for analyzing and making policy recommendations about providing access to breakthrough therapies like psilocybin and MDMA.

The House Finance Committee advanced the legislation to Sen. Chris Lee (D) on a 15-0 vote Tuesday. The measure, which passed the Senate last month by a 24-0 vote, will next go to the House floor before returning to the Senate for that chamber to consider final amendments.

The bill would create Creative Mental Health Therapy, a two-year review of the current scientific literature, supporting additional clinical research and developing policy recommendations for the “safe, ethical, and culturally informed implementation” of a psychedelic therapy program.

“The Legislature believes in addressing the mental health crisis affecting the State’s residents, particularly among veterans, first responders and trauma survivors,” SB 3199 reads. “Suicide remains the leading cause of preventable death, and the State must explore all safe and effective treatment options supported by scientific evidence.”

Given that the Federal Food and Drug Administration (FDA) has designated psilocybin and MDMA as breakthrough therapies in the treatment of serious mental health conditions, which may be subject to future control under the Controlled Substances Act (CSA), Hawaii’s legislation states that the state must “proactively prepare public health, clinical and research systems for safe and equitable implementation.”

The state Department of Health said in House committee testimony that it supports the bill, noting that in light of the FDA’s action on psychedelics, it is “prudent for Hawaii to assess research readiness, regulatory implications, workforce development and culturally informed implementation pathways” before any federal rescheduling of the substances.

The Governor’s Office of Wellness and Resiliency said the bill “has an important opportunity to begin paving a planned pathway for people who need access to life-saving treatments for trauma and other mental health issues.”

“A growing body of research demonstrates that breakthrough therapies (such as MDMA and psilocybin-assisted therapies) demonstrate high efficacy and positive clinical outcomes in the treatment of post-traumatic stress disorder, substance use disorders, end-of-life anxiety, eating disorders, depression, treatment-resistant, and additional conditions in terminally ill patients.”




Team members should include representatives from the State Department of Health (DOH), the Office of the Attorney General, the Office of Wellness and Resiliency (OWR), the University of Hawaii School of Medicine, and more.

Like the draft, the DOH would oversee the task force, an amendment approved by the House Health Committee last month makes the University of Hawaii John A. Burns School of Medicine (JABSOM) the responsible institution, and JABSOM’s nominee as the panel’s chairman.

The commission also adopted amendments suggested by the Department of Law Enforcement to say that its Division of Narcotics Enforcement — and not the Board of Pharmacy — would be responsible for changing the state’s scheduling of psychedelics after any federal reclassification, and to change the deadline for doing so from 90 days to 30 days.

Members note in their bill report that the state Agency for Health Planning and Development has expressed concern that psychedelics are illegal under federal law and that the task force should proceed with caution.

Finally, the panel made technical corrections for clarity, consistency, and style.

If ordered, it appears invoice would be It was first assembled in 2023 based on prior work by a separate psychedelic task force.With a similar goal of exploring avenues for therapeutic access in breakthrough drugs approved by the FDA such as psilocybin.


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

Meanwhile, Hawaii senators recently passed a bill to legalize low-dose, low-potency marijuanathe legislation did not advance the necessary steps before a crucial deadline, so it is dead for the year.

A separate marijuana legalization bill, SB 2421, that contained provisions under federal reform law or amendments to the state Constitution, was delayed for action. The Senate and House panels also delayed action on a measure to sell certain hemp-derived cannabinoid products.

These actions follow Senior lawmakers in the House indicated that proposals to legalize cannabis would not move forward In the 2026 session, citing the lack of sufficient support in their chamber.

Earlier this month, a Hawaii Senate committee unanimously approved legislation to allow patients immediately enter medical cannabis after submitting their recordsinstead of waiting for the cards to be delivered, as is the case under current legislation.

A Senate committee also adopted the resolutions Asking Congress to federally legalize marijuanasupport the state’s efforts to clean up people’s criminal records and take steps to make it easier for cannabis companies to access banking services.

Another Senate panel advanced separate resolutions urging the state attorney general and the health department to seek a waiver from the Drug Enforcement Administration (DEA). Hawaii is allowed to run its cannabis program without federal interference.

user photo Wikimedia/Mushroom Observer.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

Rescheduling appeal process ‘remains pending’ despite Trump’s executive order

Published

on

By











The Drug Enforcement Administration (DEA) says the marijuana redistricting appeals process “remains pending” despite President Donald Trump issuing an executive order more than three months ago ordering the attorney general to pursue reform “as expeditiously as possible.”

The DEA and reform advocates filed a joint status report Monday on the agency’s interlocutory appeal of bias and improper communications with parties opposed to the redistricting.

“To date, the Movants’ interlocutory appeal to the Administrator on the Motion for Reconsideration remains pending with the Administrator,” said attorneys representing the DEA and cannabis reform advocates who are challenging the process. “No information schedule has been established.”

The agency is responsible for establishing the information schedule. But nearly a year after a former administrative law judge granted the appeal, the DEA is once again delaying the process. This is the fifth consolidated status report, with largely identical language, that the parties have submitted under the administrative litigation order.

Read more Marijuana Moment










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media